These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 12586668)

  • 1. Cross sectional survey of meningococcal C immunisation in children looked after by local authorities and those living at home.
    Hill CM; Mather M; Goddard J
    BMJ; 2003 Feb; 326(7385):364-5. PubMed ID: 12586668
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunisation update: Meningococcal B and ACWY vaccines.
    Davidson GT; Heaton PA; Paul SP
    J Fam Health; 2015; 25(6):22-5. PubMed ID: 26749934
    [No Abstract]   [Full Text] [Related]  

  • 3. Reflections on the meningococcal group C infection immunisation campaign: views from the sharp end.
    Lansley M; Bedford H
    Vaccine; 2003 Jun; 21(21-22):2877-81. PubMed ID: 12798630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of meningococcal C conjugate vaccine use in Australia.
    Booy R; Jelfs J; El Bashir H; Nissen MD
    Med J Aust; 2007 Feb; 186(3):108-9. PubMed ID: 17309394
    [No Abstract]   [Full Text] [Related]  

  • 5. Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.
    Pollard AJ; Green C; Sadarangani M; Snape MD
    Arch Dis Child; 2013 Apr; 98(4):248-51. PubMed ID: 23482919
    [No Abstract]   [Full Text] [Related]  

  • 6. Vaccination campaign following an increase in incidence of serogroup C meningococcal diseases in the department of Puy-de-Dôme (France).
    Lévy-Bruhl D; Perrocheau A; Mora M; Taha MK; Dromell-Chabrier S; Beytout J; Quatresous I
    Euro Surveill; 2002 May; 7(5):74-6. PubMed ID: 12631934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.
    Bettinger JA; Scheifele DW; Le Saux N; Halperin SA; Vaudry W; Tsang R;
    Pediatr Infect Dis J; 2009 Mar; 28(3):220-4. PubMed ID: 19209096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Meningococcal infections. Every case a preventable tragedy].
    Bischoff A
    MMW Fortschr Med; 2008 Jun; 150(24):17. PubMed ID: 18605054
    [No Abstract]   [Full Text] [Related]  

  • 9. Meningococcal C vaccines: the Canadian experience.
    De Wals P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.
    Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT
    Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meningococcal B immunisation in New Zealand: why haven't we seen the data?
    Bolland M
    N Z Med J; 2008 Mar; 121(1270):107-9. PubMed ID: 18364764
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of the impact of serogroup C meningococcal disease vaccination program in Brazil and its regions: a population-based study, 2001-2013.
    Moraes C; Moraes JC; Silva GD; Duarte EC
    Mem Inst Oswaldo Cruz; 2017 Apr; 112(4):237-246. PubMed ID: 28327788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada.
    De Wals P; Deceuninck G; Lefebvre B; Tsang R; Law D; De Serres G; Gilca V; Gilca R; Boulianne N
    Clin Infect Dis; 2017 May; 64(9):1263-1267. PubMed ID: 28207068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the burden of serogroup C meningococcal disease in England and Wales.
    Davison KL; Ramsay ME; Crowcroft NS; Lieftucht A; Kaczmarski EB; Trotter CL; Gungabissoon U; Begg NT
    Commun Dis Public Health; 2002 Sep; 5(3):213-9. PubMed ID: 12434691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perils of launching a new vaccination campaign.
    Dobson F
    BMJ; 2014 Apr; 348():g2449. PubMed ID: 24699385
    [No Abstract]   [Full Text] [Related]  

  • 16. Meningococcal Disease: Vaccines-Who's at Risk and the Future.
    O'Malley PA
    Clin Nurse Spec; 2018; 32(1):15-18. PubMed ID: 29200035
    [No Abstract]   [Full Text] [Related]  

  • 17. Enter B and W: two new meningococcal vaccine programmes launched.
    Ladhani SN; Ramsay M; Borrow R; Riordan A; Watson JM; Pollard AJ
    Arch Dis Child; 2016 Jan; 101(1):91-5. PubMed ID: 26672098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine.
    De Wals P; Deceuninck G; Boulianne N; De Serres G
    JAMA; 2004 Nov; 292(20):2491-4. PubMed ID: 15562128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of meningococcal C conjugate vaccine in Salvador, Brazil: a case-control study.
    Cardoso CW; Ribeiro GS; Reis MG; Flannery B; Reis JN
    PLoS One; 2015; 10(4):e0123734. PubMed ID: 25874777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment.
    Wormsbecker AE; Wong K; Jamieson FB; Crowcroft NS; Deeks SL
    Vaccine; 2015 Oct; 33(42):5678-5683. PubMed ID: 26299749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.